Your Global Leader in Stem Cell Market Research
Miami, FL (September 2, 2020) — Organicell Regenerative Medicine, Inc. (OTCBB: BPSR), a clinical-stage biopharmaceutical company dedicated to the development of regenerative therapies, announced that the U.S. Food and Drug Administration (FDA) granted emergency, expanded access approval to treat two mild to moderate COVID-19 patients and one “Long Hauler” post COVID-19 patient. [Read more…]
Biotech investing has become an increasingly popular in recent years. Whether you’re new to biotech stocks or you’ve been around the block, with the recent stock market drops caused by COVID-19, now could be a good time to place your bets.
The stock market had its largest point drop in recent history on March 9, 2020. Shortly thereafter, on March 12 and March 16, there were two more record-setting point drops. Even though the market has recovered somewhat following the $2.2 trillion stimulus bill, market prices remain attractive across many sectors.
Furthermore, stem cell companies are receiving startling support for use of living therapeutics against COVID-19 induced respiratory complications, such as ARDS. The Australian company, Mesoblast, is now enrolling for a 300 person trial and the American company, Athersys, is enrolling for an even larger 400 person trial.
Under these conditions, one of the most intriguing niches within biotech investing is stem cell stocks. [Read more…]
Miami, FL (August 18, 2020) — Organicell Regenerative Medicine, Inc. (OTCBB: BPSR), a clinical-stage biopharmaceutical company dedicated to the development of regenerative therapies, announced today that it has partnered with Alternative Research Associates, LLC and Larkin Hospital in Miami, FL to initiate a randomized, double-blinded, placebo-controlled phase I/II clinical trial against COVID-19 of its lead therapeutic candidate, which has been rebranded as Zofin. [Read more…]
Miami, FL (August 6, 2020) — Organicell Regenerative Medicine, Inc. (OTCBB: BPSR), a clinical-stage biopharmaceutical company dedicated to the development of regenerative therapies, announced today that the U.S. Food and Drug Administration (FDA) approved two outpatient Emergency Investigational New Drug Applications (eINDs) for treating mild to moderate respiratory distress due to COVID-19. [Read more…]
AUSTIN, Texas — Direct Biologics, LLC, is announcing that it has received approval from FDA that it may proceed with a Phase II trial under an Investigational New Drug (IND) application for the use of ExoFlo™, a bone marrow-derived extracellular vesicle and exosome product, in the treatment of COVID-19 associated Acute Respiratory Distress Syndrome (ARDS). The ExoFlo Infusion Treatment for COVID-19 (EXIT COVID-19) Associated ARDS trial will be a multi-center, double-blind, randomized, placebo-controlled clinical trial. [Read more…]
